A study to assess risk of outpatient infections in untreated persons with multiple sclerosis, those using RTX or other disease-modifying treatments compared to matched non-MS controls.
Latest Information Update: 20 Dec 2021
At a glance
- Drugs Fingolimod (Primary) ; Glatiramer acetate (Primary) ; Interferon beta (Primary) ; Natalizumab (Primary) ; Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 20 Dec 2021 New trial record